Cixutumumab is a humanized anti-IGF-1R monoclonal antibody for the treatment of solid tumors. Cixutumumab selectively binds to membrane-bound IGF-1R, preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway.